Last reviewed · How we verify
CTP0303
CTP0303 is an investigational therapeutic in phase 3 development by Taejoon Pharmaceutical, but its specific mechanism of action is not publicly disclosed.
At a glance
| Generic name | CTP0303 |
|---|---|
| Sponsor | Taejoon Pharmaceutical Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
Without access to detailed clinical trial data or company disclosures, the precise molecular target and mechanism cannot be reliably determined. Phase 3 status indicates it has demonstrated sufficient efficacy and safety in earlier trials to warrant late-stage clinical evaluation.
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |